Kornimate/medical-research-clean huggingface dataset:
removal of surgical staples after cesarean delivery. randomized control trial.

Conditions: Cesarean Section; Wound, Infection (Following Delivery)

Summary: the optimal choice of skin closure at cesarean delivery has not yet been determined. this study aim to study the wound complications and scar healing after surgical staples removal at postoperative day 4 and day 8 . a randomized control trial.

a randomized controlled trial in which pregnant women undergoing a scheduled elective cesarean delivery were assigned to skin closure with surgical staples and were randomly assigned to the day of removal of surgical staples. postoperative day 4 vs. postoperative day 8 . outcome assessors were blinded to group allocation. scars will be evaluated after 8 weeks. primary outcome measures is patient and observer scar assessment scale (posas) scores. secondary outcome measures are complications of surgical site infection (ssi) or wound disruption (hematoma or seroma). a group of 104 women is needed in order to achieve a clinically signiﬁcant effect with a power of 80%.

Eligibility criteria:
inclusion criteria: * elective cesarean delivery * previous cesarean delivery performed using the pfannenstiel method * 36-41 weeks of gestation based on first trimester ultrasound and a viable fetus. exclusion criteria: * emergency cesarean delivery * clinical signs of infection at the time of cd, uncontrolled * vunblanaced diabetes mellitus * history of keloids
effects of wood smoke particles on influenza-induced nasal inflammation in normal volunteers

Conditions: Response of Viral Infection to Woodsmoke

Summary: this study is focused on the pathophysiology underlying the association between exposure to particulate pollutants and risk for/response to viral infection. the investigators hypothesize that exposure to wood smoke particles (wsp) enhances influenza virus-induced granulocyte and nk cell activation, via hyaluronic acid-mediated effects on ifng production. oxidant stress and viral replication may also be affected. as an nih funded victer project, the purpose of the study is also to test novel assays of granulocyte activation (doershuk lab) and lipid mediator activation (albritton lab) which have not previously been used in this type of research. healthy, nonsmoking adults age 18-40 years will be recruited. this is a randomized, placebo controlled study comparing nlf granulocyte responses to laiv administered after either wsp or clean air, in normal healthy volunteers. subjects receive either wsp or placebo (clean air), followed by a standardized dose of laiv and serial post-infection sampling of nasal lavage fluids, nasal biopsy and blood


Eligibility criteria:
inclusion criteria: 1. normal lung function, defined as (knudson 1976/1984 predicted set): fvc \> 75 % predicted for gender, ethnicity, age and height; fev1 \>75 % predicted ; fev1/fvc ratio \>0.70 and \< 0.90. 2. oxygen saturation of \> 94% 3. normal blood pressure (systolic between 140 - 90, diastolic between 90-60 mm hg) 4. symptom score no greater than 6 (out of a possible 39) for total symptom score 5. on the day of a challenge, body temperature must be no greater than 37.8 degrees, measured orally exclusion criteria: 1. a history of significant chronic illnesses (to include diabetes, autoimmune diseases, immunodeficiency state, known ischemic heart disease, chronic respiratory diseases such as chronic obstructive pulmonary disease or asthma, hypertension) 2. positive pregnancy test within 48 hours of the time of challenge 3. use of any inhaled substance (for medical or recreational purposes). nonsmokers must have been abstinent from smoking for the prior 12 months, having not smoked more than 1 pack over the course of the previous year and does not smoke at all 1 week prior to entrance in the study. 4. receipt of laiv in the current season 5. history of allergy to eggs 6. acute, non-chronic, medical conditions, including (but not limited to) pneumonia or bronchitis requiring antibiotics, febrile illnesses, flu-like symptoms must be totally resolved symptomatically for 3 weeks 7. unspecified illnesses, which in the judgment of the investigator increase the risk associated with the experimental laiv infection, will be a basis for exclusion. 8. expected exposure of subject to immunocompromised individuals (who can be infected by laiv) for the 3 weeks following laiv inoculation

Keywords: laiv flumist wood smoke
a multi-mode thermophysical immunotherapy study for breast cancer liver metastases

Conditions: Breast Neoplasms; Liver Neoplasms; Metastasis

Summary: this is a single-center, parallel-controlled clinical study designed to evaluate the safety, efficacy and impact on systemic anti-tumor immunity of a multi-mode integrated ablation system for the treatment of breast cancer liver metastases.

this is a single-center, parallel-controlled clinical study. the study plans to enroll 10 subjects, with 5 in the multi-mode ablation group (experimental group) and 5 in the conventional radiofrequency ablation group (control group). the entire study includes a screening period, treatment period and follow-up period. by comparing multi-mode ablation with conventional radiofrequency ablation, the study aims to observe the efficacy, safety of the multi-mode ablation technique in subjects and its impact on the systemic anti-tumor immunity of subjects.

Eligibility criteria:
inclusion criteria: 1. age 18-75 years, female gender; 2. pathologically confirmed breast cancer liver metastases, in patients who are unable to tolerate or refuse surgical resection; 3. the number of lesions ≤ 3, with any single lesion diameter ≤ 4cm; 4. at least an interval of 1 month since the last local treatment; 5. child-pugh class a or b; 6. ecog ps score ≤2, with an expected survival of \>3 months. exclusion criteria: 1. liver function child-pugh class c; 2. systemic widespread metastasis, with an expected survival of \< 3 months; 3. history of esophageal (gastric fundus) variceal bleeding within the past month; 4. dysfunction or failure of vital organs; 5. presence of an active infection; 6. irreparable coagulation abnormality; 7. refractory massive ascites, pleural effusion or cachexia; 8. pregnancy, altered consciousness or patients unable to cooperate with treatment; 9. previously participated in other clinical studies and still within the follow-up period; 10. any other factors deemed inappropriate for inclusion or that may affect the patient's participation in the study, as determined by the investigator.

Keywords: multi-mode thermophysical immunotherapy
xylitol - healthcare associated infection reduction in stem cell transplant patients

Conditions: Allogeneic Hematopoietic Cell Transplantation

Summary: the central hypothesis is that daily dental xylitol wipes, in addition to current oral care practice, are effective at reducing bsi from oral organisms, and decreasing the incidence of gingivitis, oral plaque, and oral ulcerations after sct.

our long-term goal is to develop and disseminate clinically relevant, and easily adoptable strategies to prevent bsi and improve outcomes after sct. the overall objective of this proposal is to identify a clinically effective strategy to prevent or reduce bsi secondary to bacterial translocation through oral injured mucosa .

Eligibility criteria:
inclusion criteria: * patients of any age undergoing sct. exclusion criteria: * prior proton or photon radiation treatment for cancer of the oral cavity, head or neck; cranial boost in patients receiving total body irradiation; known history of allergy to xylitol; inability to use a mouth rinse or dental wipes.
polyurethane foam-pink pad (rct) use in or

Conditions: Cardiac Surgery Subjects; Pressure Ulcer Prevention; Pressure Ulcer of Skin; Pressure Ulcer

Summary: king abdullah medical city has a cardiac center, and a lot of open-heart surgeries are performed there, and both polyurethane foam (pink pad) and mepilex dressing are applied to those patients. therefore, the present study was designed to compare the effects of polyurethane foam (pink pad) versus mepilex dressing for prevention of pressure ulcer in operating room.

there are two types of intervention available in king abdullah medical city for operating room pressure ulcer prevention. polyurethane foams (pink pad) are a single use system for use in surgical procedures. the system consists of a proprietary formulation for the pink foam pad, non-woven lift sheet, body straps, head rests, and boot liners. it aids hospital facilities in providing a safe and effective method of management of the patient for pressure ulcers and non-movement for patients in the trendelenburg position. mepilex border sacrum dressings are self-adherent, multilayer foam dressings designed for use on sacrum aiming to prevent pressure ulcers. the dressings are used in addition to standard care protocols for pressure ulcer prevention. all included patients received standard pu prevention according to hospital protocols, based on contextualization and adaptation of international guidelines ( european pressure ulcer advisory panel, 2021 ), which involved: assessment of pu risk through the braden scale at hospital admission,

Eligibility criteria:
inclusion criteria: * subjects ≥ 18. * willing to participate. * patients undergoing cardiac surgery. * patient who is at risk for pu development as measured with braden scale. * patient who has skin intact and having a life expectancy greater than 72 hours as per clinical judgement. exclusion criteria: * subjects under 17 * not consenting to participate * patients with suspected hypersensitivity reactions to any of the dressing formulation's ingredients. * patients who are unable to continue the study because of death or change in the care setting.

Keywords: five layers sacral foam dressing pink pad pressure ulcers patients undergoing cardiac surgery mepilex dressing
testing protocol to efficiently induce itch

Conditions: Itch

Summary: this subproject aims to evaluate a new nerve excitability protocol to induce itch in healthy controls by electrical stimulation. itch has many similarities with pain, and the nerve fibers that mediate the two sensations probably have the same morphological and excitability properties. the method used in this project will be the same as our research group uses for studying nociceptor fibers (ptt technique), but the focus is on the itch sensation. since the itch fibers also terminate in the epidermis, our ptt technique should also be able to activate itch fibers, similar to pain fibers. if itch could be effectively induced by electrical stimulation, this would generate a valuable tool for studying itch in healthy controls. the sub-project takes place in 2 sessions (2 hours each).


Eligibility criteria:
inclusion criteria: healthy men and women in the age 18-80 years who speak and understand exclusion criteria: * pregnancy or breast feeding * drug addiction defined as the use of cannabis, opioids or other drugs * previous and present neurologic, musculoskeletal or mental illnesses (e.g., epilepsy, neuropathy, fibromyalgia and depression) * skin diseases * past history of conditions possibly leading to neuropathy * inability to cooperate * current use of medications that may affect the study, e.g., analgesics * previous traumatic experience of an electrical accident * consumption of alcohol or painkillers within the last 24 hours * participation in other pain studies throughout the study period * patients with cardiac diseases (e.g., pacemaker).
time-differentiated therapeutic hypothermia

Conditions: Out of Hospital Cardiac Arrest

Summary: the purpose of this study is to determine if 48 hours of mild therapeutic hypothermia following out of hospital cardiac arrest gives a better cerebral outcome compared to 24 hours therapeutic hypothermia.

sudden out-of-hospital cardiac arrest (ooh-ca) remains a significant cause of death. however, in 2002 it was in two clinical trials demonstrated that mild therapeutic hypothermia in comatose ooh-ca victims yields a better cerebral outcome measured by cerebral performance category score (cpc) after 6 month. the optimal mild hypothermia treatment time is however not known. the two trials from 2002 apply the treatment for 12 and 24 hours respectively. in newborns with cerebral hypoxic damage the standard treatment time is 72 hours. it is therefore relevant to investigate the influence of the treatment time on the cerebral outcome in ooh-ca victims. in the present study cerebral outcome after mild therapeutic hypothermia (target temperature 33 degrees centigrade) in ooh-ca patients for 24 is compared to outcome after 48 hours of mild hypothermia. the main outcome parameter is mortality and cpc score measured 6 month after the treatment.

Eligibility criteria:
inclusion criteria: 1. out of hospital cardiac arrest of suspected cardiac origin 2. return of spontaneous circulation (rosc) 3. glasgow coma score \< 8 4. estimated time interval from cardiac arrest to rosc ≤ 60 min exclusion criteria: 1. ooh-ca of suspected origin other than cardiac 2. in hospital cardiac arrest 3. terminal disease 4. coagulation disorders 5. unwitnessed asystolia 6. time from cardiac arrest to start of hypothermia treatment \> 240 min 7. gcs ≥ 8 8. pregnancy 9. persistent cardiogenic shock (systolic blood pressure \< 80 mmhg despite inotropic treatment and aortic balloon pump). 10. cpc 3-4 before cardiac arrest 11. acute intra cerebral bleeding 12. acute stroke 13. acute coronary artery bypass grafting
mydc/pdc in stage iii melanoma patients

Conditions: Melanoma

Summary: this is an interventional study to test the immunogenicity of combined adjuvant mydc and pdc vaccination versus adjuvant mydc or pdc vaccination alone in stage iii melanoma patients.

stage lll melanoma patients will receive pdc (arm a, n=10), mydc (arm b, n=10) or combined pdc/mydc (arm c, n=10). subsequent vaccinations will be performed according to the protocol: 2 biweekly vaccinations of intranodal injections with pdc, mydc or the combination with pdc and mydc. after each vaccination the investigators will examine peripheral blood for proliferative and humoral klh immune responses. after the vaccinations, a dth with peptide loaded blood dc is performed from which biopsies are taken for t cell analysis. lf patients remain disease free, the investigators will repeat this cycle with a 6 months interval up to a total of three cycles. lf a tumor recurrence occurs a biopsy will be taken for laboratory evaluation.

Eligibility criteria:
inclusion criteria: * stage iii melanoma * who performance status 0-1 * radical lymph node dissection is schedule or performed within 12 weeks prior to start of study treatment exclusion criteria: * irresectable disease * any concurrent adjuvant therapy * concomitant use of oral immunosuppressive drugs * autoimmune diseases
nrc:improving healthcare for cognitively impaired elders and their caregivers

Conditions: Alzheimer Disease; Nurse Training

Summary: an multi-stage mixed-method design will be employed to obtain both qualitative and quantitative data to address two study aims: (1) evaluate and refine the delivery reducing disabilities in alzheimer's disease (rd- ad) training to advanced practice nurses and (2) evaluate and refine the implementation of rd-ad by advanced practice nurses in their medical settings.

two waves of apns (25 each wave/total 50) will receive rdad training and be queried pre and post- training using both qualitative and quantitative procedures to determine: (1) is rdad training successfully received by advanced practice nurses? (2) do they report it as relevant to improving the care they deliver to persons with alzheimer's disease and related dementias (adrd)? (3) does rdad training of advanced practice nurses improve their level of knowledge about adrd, their skills in providing adrd care, and their level of confidence in providing this care? a subset of advanced practice nurses (5 per wave, total of 10) will be recruited to implement rdad as part of their ongoing care of persons with adrd.

Eligibility criteria:
inclusion criteria: * licensed by the washington state department of health as an advanced registered nurse practitioner (arnp), * hold a board certification as a gerontological nurse practitioner, adult nurse practitioner, or family nurse practitioner, * work at least half time (0.50 fte) in a clinical setting (primary care, internal medicine, sub-specialty, medical home), with a panel consisting of over 25% of patients over 65 years of age, * have no expectation for termination over the course of the study; and * agree to participate in all phases of the rdad translational program. exclusion criteria: * na
exopulse mollii suit and fibromyalgia

Conditions: Fibromyalgia, Primary

Summary: fibromyalgia is a debilitating pain condition that is characterized by the chronic occurrence of pain affecting the musculoskeletal system, a sensitivity to pressure stimuli, and a low threshold to noxious stimuli. the topography of pain is widespread, although it could be more pronounced in some bodily regions. besides pain, patients suffer from a wide range of symptoms, including fatigue, anxiety and depression manifestations, and altered quality of life. facing these debilitating symptoms, the available therapeutic strategies for treating pain and associated manifestations are usually faced with limited efficacy and numerous side effects. for these reasons, non-invasive stimulation techniques, namely transcutaneous stimulation by means of exopulse mollii suit, might be of help in this context. the investigators designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of "active" versus "sham" exopulse mollii suit. a 2-week washout period should be enough to prevent a potential carry over effect. after this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of exopulse mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes.


Eligibility criteria:
inclusion criteria: * patients aged between 18 and 75 years, with a definite diagnosis of fibromyalgia according to the american college of rheumatology (acr) 2010 criteria, set for at least one month * patients should be french speakers, able to understand verbal instructions, and affiliated to the national health insurance exclusion criteria: * patient with vas \< 4 * patient included in another research protocol during the study period * patient unable to undergo medical monitor for the study purposes due to geographical or social reasons * patient with contraindication to wearing exopulse mollii suit (e.g., cardiac stimulator, a ventriculoperitoneal shunt, intrathecal baclofen pump, pregnancy, and/or body mass index above 35 kg/m2) * patient with other somatic or psychiatric diagnoses other than anxiety and depression (e.g., arrhythmias, uncontrolled epilepsy, other diseases causing osteoarticular and muscular pain) * any change in the pharmacological therapy in the last three months * introduction of a medical device other than exopulse mollii suit during the study period * patient under juridical protection (" mesure de protection judiciare : tutelle, curatelle, sauvegarde de justice ")
gwas identified susceptibility loci for glucocorticoid-induced fhn in the chinese population

Conditions: Femur Head Necrosis; Adverse Effect of Glucocorticoids and Synthetic Analogues

Summary: this is a observation clinical trial. we are collecting the patients with glucocorticoid. they were divided into the experiment group (with femur head necrosis) and control group (without femur head necrosis).then, we will analyse the patients' genome with genome-wide association study (gwas). our purpose is to find susceptibility loci for glucocorticoid-induced femur head necrosis in the chinese population.


Eligibility criteria:
inclusion criteria: 1. subject has given the written informed consent voluntarily; 2. male or female between 18\~60 years; 3. candidate is clinically diagnosed as avascular osteonecrosis of the femoral head (onfh), in reference to the diagnostic criteria set forth by experts' consensus on the diagnosis and treatment of osteonecrosis of the femoral head in adults (edition 2012); 4. patient with history of glucocorticoid therapy, in form of oral, muscular or vascular administration, should have total dose equivalent to ≧2000 mg of prednisone, and maintain on that dose for ≦3 months. exclusion criteria: 1. subject is not in conformity with diagnostic criteria for onfh; 2. patient has a history of trauma in the lower limbs or pelvis; 3. prolonged addiction to alcohol; 4. concurrent with renal failure, organ transplant, graft versus host disease, inflammatory bowel disease, hiv infection or leukemia; 5. patient with familial idiopathic onfh; 6. subject suffers from a fatal disease, with life expectancy \< 2 months; 7. woman of child-bearing potential, who is pregnant, in preparation of pregnancy or breast-feeding during the study period; 8. other patients deemed ineligible at the discretion of the investigator.

Keywords: adverse effect of glucocorticoids femur head necrosis susceptibility gwas
a preliminary randomized study of tianjiu (auto-moxibustion) effects in patients with intradialytic hypotension

Conditions: Intradialytic Hypotension

Summary: intradialytic hypotension (idh) is a most frequent complication of hemodialysis (hd) and may contribute to cardiovascular events and high mortality. the etiology of idh is multifactorial; therefore, it remains a challenging problem in the management of hd patients. because moxibustion (mo) at specific points can influences hemodynamics, we hypothesize that tianjiu (auto-mo) at the traditionally used meridian points will reduce the severity of hypotension in patients who undergo hd.

in this clinical trial, 45 patients had idh were divided randomly into two (auto-mo therapy and control) groups for 4 weeks. in the tianjiu (auto-mo) group, the patients were applied at 3 points (conception vessel 4, and kidney 1) for 3-4 h during hd sessions. all number of episodes complicated by symptomatic idh during hd sessions and the number of idh-related nursing interventions (trendelenburg position, manual reduction of ultrafiltration rate, infusion of isotonic saline or hypertonic fluid, lowering of dialysate temperature) in a session were recorded. pre- and post-dialysis systolic and diastolic bp, pre- and post-dialysis body weights, interdialytic weight gain, percentage of target ultrafiltration achieved, patient's subjective assessment of the degree of fatigue after dialysis (scale from 0 to 10; 0, not at all, 10, extremely) and recovery time from fatigue after dialysis were measured at the 0, 2nd, 4th and 6th week.

Eligibility criteria:
inclusion criteria: * the subjects enrolled in the study were patients undergo regular hemodialysis, ranging from 20-75 years of age, at nephrologic clinic in kcgmh. these patients have experienced \> 3 episodes of intradialytic hypotension in recent two months. exclusion criteria: * (1)confounding diseases such as sepsis, cancer, decompensated liver cirrhosis, respiratory failure, and heart failure(nyha\>3), (2) disturbed consciousness, (3) pregnancy, (4) can't tolerate the heat and allergy to automoxibustion,

Keywords: auto-moxibusition, intra-dialytic hypotension, hemodialysis